Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

Baker, Matthew; Chaichian, Yashaar; C. Genovese, Mark; K. Derebail, Vimal; S. Rao, Panduranga; Chatham, Winn; Bubb, M; Lim, Sam; Hajian, Hooman; Gurtovaya, Oksana; D. Patel, Uptal; A. Tumlin, James

doi:10.1136/rmdopen-2020-001490

Public

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

Published in RMD Open • Dec 1, 2020

Authors:

Matthew Baker

Yashaar Chaichian

Mark C. Genovese

Abstract

OBJECTIVES: Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking. This trial assessed the preferential Janus kinase 1 (JAK1) inhibitor filgoti...

Subject

Medicine

Systemic lupus erythematosus

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!